Navigation Links
Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy

CARY, N.C., Sept. 1, 2015 /PRNewswire/ -- Medfusion, Inc., a patient engagement platform dedicated to facilitating the relationship between doctors and patients, today announced a $3 million investment from two Durham, N.C.-based venture capital firms.  

"We welcome the financial strength and business association with Bull City Venture Partners and Hatteras Venture Partners," said Steve Malik, Medfusion Founder and Executive Chairman. "Both firms' experience working at the intersection of the software, healthcare and life sciences industries will help Medfusion accelerate our goal of using technology to make healthcare easier for everyone."

Medfusion has evolved from a patient portal business into a robust patient engagement platform, complete with a new portal interface, a patient-focused revenue cycle offering—Medfusion Pay—and the introduction of Medfusion's first consumer mobile application, Medfusion Plus. This new application allows patients to aggregate their disparate health records, as well as those of their family members, on their mobile devices.

"We have a distinguished history of providing innovative technology to healthcare providers—allowing them to engage and communicate with their patients," said Vern Davenport, Medfusion Chief Executive Officer. "And over the past few years, we've watched 'consumerism' take hold in the healthcare industry as a result of federal legislation, as well as healthcare cost shifting from employers to patients.

"Our customers are moving to new business models in healthcare with changing reimbursements—all while assuming more risk than ever before," Davenport continued. "Further, their patients are assuming more of the cost burden through high deductible health plans and other insurance tools. We must adapt as an industry to these major shifts, and with our new direction, we're confident that Medfusion will lead the way to meet the needs of both providers and patient consumers through our platform and mobile initiatives."

David Jones, Partner, Bull City Venture Partners, commented, "We've known Steve (Malik) and Vern (Davenport) for a number of years and respect the success that they've achieved as a result of their strategic thinking, strong networks and business acumen. We are impressed with the resources Medfusion is dedicating to grow its core competencies to serve provider organizations and consumers. This is an exciting time to be in healthcare, and we're proud to be part of the Medfusion Team."

John Crumpler, General Partner, Hatteras Venture Partners, expressed similar sentiment. "We're very impressed with the technology development at Medfusion over the past couple of years, the people leading the efforts, and the associated process and quality rigor. But just as important, we're impressed with the vision of the organization. Medfusion could have been satisfied with being the leader in patient portals and patient engagement, as rated in the recent KLAS report, but they knew the company could expand to meet even more of the changing and complex needs of the industry. We look forward to working with this great team."

As part of the investment, both Jones and Crumpler have joined the Medfusion Board.

About Bull City Venture Partners
Bull City Venture Partners is a venture capital firm focused on partnering with the best technology entrepreneurs to create market-leading companies. Learn more at

About Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC with a focus on seed and early stage opportunities in biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. The firm has over $350 million under management in five venture capital funds. Hatteras is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed and early stage investing and company formation. Learn more at

About Medfusion
Medfusion delivers transformative technology and services that put patients in control of their healthcare and enable providers to thrive in a value-based healthcare delivery environment. Our patient portal, evolving platform and mobile capabilities connect more than 11 million patients to their healthcare providers—facilitating bi-directional communication, enhancing patient engagement and improving the practice's financial operations. For more information, please visit

Logo -


SOURCE Medfusion
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas
2. AgBiome Secures $34.5 Million Series B Financing
3. Cold Genesys Secures Series B Investment
4. SiteOne Therapeutics Secures Investment from Bozeman-based Next Frontier Capital
5. InSphero AG Secures CHF 20 Million Series C Financing
6. MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries
7. BioAmber Secures Best-In-Class Technology for Planned BDO/THF Plants
8. CannLabs Secures $750,000 Line Of Credit
9. MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development
10. LABSCO Secures Alliance With Siemens Healthcare Diagnostics
11. MediVet America Secures Exclusive Worldwide License with Nanofiber Veterinary
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):